Close

Press Releases

Pfizer Extends Subsequent Offering Period of Tender Offer to Acquire Icagen, Inc.

Pfizer Inc. and Icagen, Inc. announced today that Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp., has extended the expiration date of the subsequent offering period of its tender offer for all outstanding shares of common stock of Icagen for...

Mayo Clinic Teams with Glowing Cats Against AIDS, Other Diseases

Mayo Clinic researchers have developed a genome-based immunization strategy to fight feline AIDS and illuminate ways to combat human HIV/AIDS and other diseases. The goal is to create cats with intrinsic immunity to the feline AIDS virus. The...

Exelixis Announces Webcasts of Upcoming Investor Conference Presentations Exelixis Inc.

Exelixis, Inc. announced today that Michael Morrissey, PhD, the company’s president and chief executive officer, will present at two upcoming investor conferences.  Morgan Stanley Global Healthcare Conference: Exelixis’ presentation will take place at 10:20...

Sucampo and Numab Sign Drug Discovery Collaboration Sucampo Pharmaceuticals Inc. and Numab AG

Sucampo Pharmaceuticals, Inc. an international pharmaceutical company, and Numab AG today announced that Sucampo’s wholly owned subsidiary, Sucampo AG, and Numab AG, have entered into a research and development collaboration that provides Sucampo with access to Numab’s proprietary...

Trophos completes patient enrolment in pivotal efficacy study of olesoxime in Spinal Muscular Atrophy

Marseille France, September 8, 2011 - Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today the completion of patient enrolment in the...

Over 65% of Physicians Have Used Social Media to Support their Professional Practice

Physicians are highly engaged with social media for both personal and professional use, according to a 4,033-clinician study authored and conducted by QuantiaMD, the largest mobile and online physician community, and Care Continuum Alliance, an international association for...

BARDA Partners to Develop New Class of Antibiotic U.S. Department of Health and Human Services

The federal government today issued a contract for advanced research and development of a dual-purpose broad spectrum antibiotic with potential to treat illnesses caused by bioterrorism threats such as plague and tularemia, as well as more certain life-threatening...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »